Background: Second generation direct acting-antivirals are promoting effective and safe treatments for chronic hepatitis C patients.
Objective: We aimed to conduct a systematic review of case reports and cases series to evaluate the safety of the drugs, highlighting the compilation of AE not previously reported in others reviews.
Method: The search was performed in four electronic databases and included only case reports and cases series that evaluated interferon-free therapies and provided safety outcomes.
Results: Initially, 1,235 records were retrieved, and after screening 30 studies were included for analysis (23 case reports and 7 cases series). A total of 39 patients were included, receiving eight different interferon-free treatments. Nineteen patients discontinued treatment (only 8 of these achieved treatment response). Other 19 patients achieved SVR without discontinued. It were observed rare adverse events, including breast hypertrophy, retinopathy, and drug induced infection. Some patients were in advanced stage of the disease, and therefore were unable to withstand the treatment due to the appearance of complications.
Conclusion: In this sense, it is important to monitor the use of these drugs that can favor the appearance of serious AE. (PROSPERO registration number CRD42016051680).